-0.5 C
Munich
Friday, January 21, 2022

MedPlus IPO subscribed 52.59 times on last day of offer: Check latest subscription status | Markets News

Must read


New Delhi: The initial public offering of pharmacy retail chain MedPlus Health Services Ltd was subscribed 52.59 times on the last day of subscription on Wednesday.

The Rs 1,398.3-crore IPO received bids for 66,13,67,268 shares against 1,25,75,154 shares on offer, according to an update on the NSE.

Qualified institutional buyers (QIBs) received a whopping 111.89 times subscription, while non-institutional investors 85.33 times and the retail individual investors (RIIs) category was subscribed 5.23 times.

The IPO had a fresh issue of up to Rs 600 crore and an offer-for-sale of up to Rs 798.30 crore.

The price range for the IPO was Rs 780-796 per share.

The company on Friday mobilised Rs 418 crore from anchor investors.

The proceeds from the fresh issue will be used for funding the working capital requirements of the company’s subsidiary Optival.

MedPlus was founded in 2006 by Gangadi Madhukar Reddy, who is the company’s managing director and chief executive officer.

The Hyderabad-based pharmacy retailer offers a wide range of products, including pharmaceutical and wellness products, such as medicines, vitamins, medical devices and test kits, and FMCG products like home and personal care items, including toiletries, baby care products, soaps and detergents and sanitisers.

Medplus was also the first pharmacy retailer in India to offer an omnichannel platform and continues to scale up its retail store network. Also Read: Cabinet’s nod to PLI for semiconductor will strengthen Aatmanirbhar Bharat Programme: PM Modi

Axis Capital, Credit Suisse Securities (India), Edelweiss Financial Services and Nomura Financial Advisory and Securities (India) were the managers to the offer. Also Read: Aadhaar Card Update: Here’s how to change date of birth in few simple steps

Live TV

#mute





Source link

- Advertisement -spot_img

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisement -spot_img

Latest article